EUCTR2010-024164-18-DE进行中（未招募）不适用
Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel
niversity Medical Center Hamburg-Eppendorf0 个研究点开始时间: 2011年3月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Patients must provide written informed consent
- •Age = 18 years
- •Patients must have histological proven, hormone-refractory prostate cancer
- •Patients must have failed prior therapy with docetaxel or must be ineligible for treatment with docetaxel
- •Patients must have ECOG performance status = 2
- •Patients must not have received any prior therapy targeting EGFR or HER2
- •Patients must have adequate bone marrow, renal and hepatic function
- •Patients must not have a history of severe heart disease
- •Patients must not have had a myocardial infarction within the previous six months
- •Patients must have normal left ventricular ejection fraction (LVEF = normal limit of institution)
- •Patients must not have symptomatic brain or leptomeningeal metastatic disease
- •Patients must have recovered from previous treatment-related adverse effects to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) grade = 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 37
排除标准
- •Prior treatment with EGFR/HER2-targeted small molecules or antibodies, i.e. trastuzumab and/or lapatinib
- •Known pre-existing interstitial lung disease
- •Radiotherapy, chemotherapy, hormone therapy (with the exception of GnRH agonists), immunotherapy or surgery (other than biopsy) within 4 weeks prior to start of treatment with BIBW2992. GnRH-agonists are allowed at the discretion of the investigator.
- •Active brain metastases (defined as stable for < 4 weeks and/or symptomatic and/or requiring changes of treatment with anticonvulsants or steroids within the past 4 weeks and/or leptomeningeal disease). Patients with known history of brain metastases should undergo a baseline brain image to ensure that the disease is stable.
- •Any other current malignancy or malignancy diagnosed within the past five (5) years (other than non-melanomatous skin cancer).
- •Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom, e.g. Crohn's disease, malabsorption or CTC grade = 2 diarrhoea of any aetiology.
- •History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation.
- •Cardiac left ventricular function with resting ejection fraction of less than 50%.
- •Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient’s safety or interfere with the evaluation of the safety of the test drug.
- •Absolute neutrophil count (ANC) < 1500 / mm³.
- •Platelet count < 75,000 / mm³
- •Calculated creatinine clearance < 60 ml / min (using Cockcroft-Gault formula for GFR estimate, see appendix 1) or serum creatinine > 1.5 times upper limit of normal.
- •Uncontrolled hypercalcemia
- •Patients unable to comply with the protocol.
- •Known hepatitis B infection, known hepatitis C infection or known HIV carrier.
- •Known or suspected active drug or alcohol abuse.
- •Requirement for treatment with any of the prohibited concomitant medications listed in section 4.2.2.1 of the protocol.
- •Any contraindications for therapy with BIBW 2992.
- •Known hypersensitivity to BIBW 2992.
- •Use of any investigational drug within 4 weeks of start of treatment.
研究者
相似试验
进行中（未招募）
2 期
Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclinesMedDRA - 10027475 (LLT): Metastatic breast cancerC50.9Breast, unspecifiedDRKS00003549niversitätsklinikum Magdeburg2
进行中（未招募）
1 期
BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expressioMetastatic breast cancer patients with intermediate HER2 expression (IHC 2+, HER2 FISH-negative)MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001765-41-DEMedizinische Fakultät der Otto-von-Guericke Universität Magdeburg Universitätsklinikum Magdeburg A.ö.R.
进行中（未招募）
不适用
Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer that developed progressive disease while on therapy or within 4 weeks after termination of an irinotecan based regimen. - MAURICEEpidermal Growth Factor Receptor (EGFR) expressing, metastatic colorectal cancerMedDRA version: 7.1Level: LLTClassification code 10052362EUCTR2005-001362-14-BEMerck KGaA46
进行中（未招募）
不适用
Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer that developed progressive disease while on therapy or within 4 weeks after termination of an irinotecan based regimen. - MAURICEEUCTR2005-001362-14-ATMerck KGaA46
进行中（未招募）
不适用
Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer that developed progressive disease while on therapy or within 4 weeks after termination of an irinotecan based regimen. - MAURICEEpidermal Growth Factor Receptor (EGFR) expressing, metastatic colorectal cancerMedDRA version: 7.1Level: LLTClassification code 10052362EUCTR2005-001362-14-DEMerck KGaA46